| Recruiting | A Study of Elenestinib in Healthy Adult Female Participants Healthy Participants | Phase 1 | 2026-02-03 |
| Not Yet Recruiting | An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM) Indolent Systemic Mastocytosis | — | 2026-02-01 |
| Recruiting | A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany Indolent Systemic Mastocytosis | — | 2025-12-09 |
| Recruiting | Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations Clonal Mast Cell Disease, KIT D816V Mutation, Suspected KITD816V Mutated Clonal Mast Cell Disease | — | 2025-10-17 |
| Recruiting | Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) Chronic Inducible Urticaria, Chronic Spontaneous Urticaria | Phase 2 | 2025-05-28 |
| Completed | Study of BLU-808 in Allergic Rhinoconjunctivitis Allergic Rhinoconjunctivitis | Phase 2 | 2025-04-14 |
| Recruiting | Avapritinib Rollover Study Mastocytosis, Systemic | Phase 4 | 2024-11-28 |
| Completed | Study of BLU-808 in Healthy Adult Participants Healthy Participants | Phase 1 | 2024-08-07 |
| Terminated | Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Advanced Systemic Mastocytosis | Phase 1 | 2023-09-25 |
| Completed | A Drug-drug Interaction Study of Avapritinib and Midazolam Gastrointestinal Stromal Tumors, GIST, Non-resectable Advanced Solid Tumors | Phase 1 | 2022-08-24 |
| Terminated | (VELA) Study of BLU-222 in Advanced Solid Tumors Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification | Phase 1 | 2022-04-07 |
| Terminated | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms | Phase 1 | 2022-03-04 |
| Completed | A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling Solid Tumor, Unspecified, Child, Relapsed Solid Neoplasm, CNS Tumor | Phase 1 / Phase 2 | 2022-02-24 |
| Terminated | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms | Phase 1 | 2022-01-13 |
| Recruiting | (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Ma Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis | Phase 2 / Phase 3 | 2021-11-30 |
| Completed | (PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mas Systemic Mast Cell Activation, KIT D816V Mutation | — | 2021-06-29 |
| Terminated | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms | Phase 1 | 2021-06-29 |
| Completed | Study for Patients Previously Treated in Avapritinib Clinical Trials Gastrointestinal Stromal Tumors | Phase 4 | 2021-05-21 |
| Completed | Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematological Neoplasm | — | 2020-12-02 |
| Unknown | External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patien RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung | — | 2020-12-01 |
| Active Not Recruiting | (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Ty Indolent Systemic Mastocytosis | Phase 2 | 2019-04-16 |
| Completed | Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults Healthy Volunteers | Phase 1 | 2019-02-12 |
| Completed | (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematologic Neoplasm | Phase 2 | 2018-11-21 |
| Completed | (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIS GIST | Phase 3 | 2018-03-26 |
| Completed | (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Aggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease, Mast Cell Leukemia | Phase 1 | 2016-03-10 |
| Completed | Mast Cell Connect: A Registry for Patients With Mastocytosis Mastocytosis | — | 2015-11-01 |
| Completed | (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Re Gastrointestinal Stromal Tumors (GIST), Other Relapsed or Refractory Solid Tumors | Phase 1 | 2015-08-01 |
| Completed | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma Hepatocellular Carcinoma (HCC) | Phase 1 | 2015-07-31 |
| No Longer Available | Expanded Access Program for Avapritinib Solid Tumors | — | — |
| Approved For Marketing | Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST GIST | — | — |
| Approved For Marketing | Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC Non-Small Cell Lung Cancer, Medullary Thyroid Cancer | — | — |